Sign in Subscribe
Chemotherapy

IMUNON Presents Promising Phase 2 Data for Gene-Based IL-12 Immunotherapy in Advanced Ovarian Cancer

Strategic Insights

— 1 min read

IMUNON, Inc. has unveiled promising Phase 2 translational data for its gene-based interleukin-12 (IL-12) immunotherapy, IMNN-001, in patients with newly-diagnosed, advanced ovarian cancer. The OVATION 2 Study demonstrated significant increases in IL-12, interferon-gamma, and tumour necrosis factor-alpha levels within the tumour microenvironment. These findings highlight the therapy's tumour-targeted effect and favourable safety profile.

Key Takeaways:

  • The OVATION 2 Study evaluated 112 participants with newly-diagnosed, advanced ovarian cancer treated with IMNN-001 alongside standard neoadjuvant and adjuvant chemotherapy.
  • The study demonstrated a 27-fold increase in IL-12 levels, a 62-fold rise in interferon-gamma (IFN-?) levels, and a 36-fold increase in tumour necrosis factor-alpha (TNF-?) levels within the tumour microenvironment.
  • IMNN-001 utilises Imunon's proprietary TheraPlas platform, enabling localised IL-12 secretion to combat peritoneal tumours effectively while minimising systemic exposure.
  • The therapy aims to address epithelial ovarian cancer, a malignancy impacting approximately 20,000 women annually in the United States, with advanced-stage survival rates remaining alarmingly low.
  • IMUNON has initiated its Phase 3 OVATION 3 trial, which aims to confirm IMNN-001's clinical benefit in improving survival and reducing recurrence in this high-risk patient population.

Statistics:

  • 112 participants were enrolled in the OVATION 2 Study.
  • The study demonstrated a 27-fold increase in IL-12 levels, a 62-fold rise in interferon-gamma (IFN-?), and a 36-fold increase in tumour necrosis factor-alpha (TNF-?) levels within the tumour microenvironment.
  • IMUNON aims to recruit participants for the Phase 3 OVATION 3 trial, which will confirm the clinical benefit of IMNN-001 in improving survival and reducing recurrence in ovarian cancer patients.

Sources:

  • M2 EQUITYBITES-June 19, 2025-IMUNON unveils promising Phase 2 translational data for IMNN-001 in advanced ovarian cancer (C)2025 M2 COMMUNICATIONS
  • ((Comments on this story may be sent to info@m2.co.uk))

Read more